This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Here's Why Merck (MRK) is Outperforming Its Industry Of Late
by Zacks Equity Research
Merck's shares are up 11.9% this year so far on strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.
Alexion Wins EC Nod for Soliris in Nervous System Disorder
by Zacks Equity Research
Alexion (ALXN) receives EC approval for the label expansion of lead drug, Soliris, for the indication of rare, devastating disorder of the central nervous system.
Top Ranked Momentum Stocks to Buy for August 28th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 28th.
Medicines Company's Inclisiran Succeeds in Pivotal Study
by Zacks Equity Research
The Medicines Company's (MDCO) PCSK9 inhibitor, inclisiran, meets primary endpoint of LDL-C reduction in a pivotal study. Shares up.
Amgen to Buy Celgene's Otezla for $13.4B: Is it a Good Buy?
by Zacks Equity Research
Amgen's (AMGN) purchase of Celgene's blockbuster psoriasis drug, Otezla is likely to strengthen its position in the immunology space.
Company News for Aug 27, 2019
by Zacks Equity Research
Companies in the news are: AMGN, PBI, BYND, SRCI, PDCE
Amgen to Buy Celgene's Otezla: 5 ETF Drugs
by Sweta Killa
Amgen agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash.
Alexion (ALXN) Down 3.2% After Amgen Buys Otezla From Celgene
by Zacks Equity Research
Alexion's (ALXN) shares dip after gaining steam on rumors of a potential acquisition by Amgen last week.
Bristol-Myers Announces Sale of Celgene's Otezla to Amgen
by Zacks Equity Research
Bristol-Myers (BMY) announces that Celgene will sell psoriasis drug, Otezla, to Amgen in connection with the ongoing regulatory approval process.
Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FLQL
Top Ranked Momentum Stocks to Buy for August 26th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 26th.
Amgen Presents Positive Data From Rituxan Biosimilar Study
by Zacks Equity Research
Amgen (AMGN) markets Mvasi and Kanjinti, biosimilar versions of Avastin and Herceptin, respectively in the United States, and Kanjinti and Amgevita, biosimilar of Humira, in the EU.
Amgen (AMGN) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Allergan is Outperforming Its Industry Of Late
by Zacks Equity Research
Allergan's (AGN) pending merger with AbbVie, positive pipeline and regulatory updates and increase in sales guidance twice are driving shares up this year.
AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA
by Zacks Equity Research
AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives FDA approval for treating rheumatoid arthritis under the trade name of Rinvoq. Shares up.
Amgen (AMGN) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Amgen (AMGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More
by Zacks Equity Research
Key highlights of the past week include collaborations, and other regulatory and pipeline news.
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
Top Ranked Income Stocks to Buy for August 14th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, August 14th.
Here's Why Amgen Stock is Outperforming Its Industry Of Late
by Zacks Equity Research
Favorable patent ruling related to Enbrel and strong second-quarter results drive Amgen (AMGN) stock 22.6% higher in the past three months.
Should Value Investors Choose Amgen (AMGN) Stock Now?
by Zacks Equity Research
Let's see if Amgen (AMGN) stock is a good choice for value-oriented investors right now from multiple angles.
Is Amgen (AMGN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (AMGN) Outperforming Other Medical Stocks This Year?
Will Amgen Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Amgen.
Mergers & Acquisitions Take Center Stage in Biotech Industry
by Zacks Equity Research
Mergers & acquisitions are in focus in the biotech industry as it undergoes a wave of consolidation.
Amgen Wins Enbrel U.S. Patent Litigation Against Novartis
by Zacks Equity Research
Despite lower demand hurting volumes of Enbrel, it remains the largest drug for Amgen (AMGN). A district court decision prevents Novartis from launching Erelzi, its biosimilar version of Enbrel.